AI-Driven Drug Discovery: Precision, Agents, and Pharma Partnerships
Genesis Molecular AI leaders discuss the strategic shift toward sub-angstrom precision, physics-informed synthetic data, and agentic workflows in drug discovery. The episode outlines how AI companies are commercializing through pharma partnerships, overcoming GPU bottlenecks, and redefining industry benchmarks for viable therapeutic development.
